Numbness, tingling, and burning in the hands and feet are common long-term problems for colorectal cancer survivors. For many people, these sensations began during chemotherapy and did not fully resolve after treatment ended. This condition is called chemotherapy-induced peripheral neuropathy, or CIPN. In colorectal cancer, it most often results from oxaliplatin-a platinum-based drug used in FOLFOX and CAPOX, the standard chemotherapy regimens for stage II and stage III disease.
CIPN can affect grip strength, balance, and routine activities such as writing and walking. Symptoms often persist for years after treatment ends. This article covers what research has found on curcumin, quercetin, and B vitamins as potential support options for CIPN in colorectal cancer survivors. It does not take the place of medical care; it describes what the science has shown so far.
| Axis | Curcumin | Quercetin | Vitamin B6 / B12 |
|---|---|---|---|
| Stage of evidence | Preclinical (oxaliplatin); 1 RCT in pediatric vincristine patients | Preclinical; 1 registered clinical trial (NCT02989129) | Prospective cohort in 242 CRC patients on oxaliplatin; RCT for vincristine |
| Proposed mechanism | Antioxidant; NF-kB inhibition; reduces nerve drug accumulation | AMPK/PGC-1alpha pathway; antioxidant; anti-inflammatory | Myelin sheath synthesis; neurotransmitter cofactor |
| Dose in research setting | 3 mg/kg twice daily, oral capsules (pediatric RCT) | 30-60 mg/kg/day (rat models); human dose not standardized | B6 plasma status tracked; no therapeutic dose established for CIPN |
| Key safety note | May interact with anticoagulants at high doses; low standard oral bioavailability | May inhibit drug transporters; discuss with oncologist | High-dose B6 may itself cause neuropathy; monitor B12 in metformin users |
Table sources: Curcumin RCT dose from PMC11853498. Quercetin animal dose from PMC7966726. B6 cohort from PMID 39886163.
How Common Is CIPN After Colorectal Cancer Treatment?
CIPN is one of the most widely reported long-term side effects of oxaliplatin-based chemotherapy. A multicenter cross-sectional study found that 31.3% of colorectal cancer patients still had sensory CIPN five years after completing adjuvant FOLFOX chemotherapy. Symptoms changed little over those five years, so many survivors live with lasting nerve problems long after treatment ends.
A population-based registry study found that 9% of colorectal cancer survivors reported painful CIPN and 22% reported non-painful CIPN. Survivors with painful CIPN had worse scores on overall quality of life, physical functioning, and social functioning. Approximately 28% of those with CIPN reported moderate to severe difficulty with walking, and 23% had significant problems with hand function.
These numbers show why supportive approaches to CIPN management receive ongoing research attention. Currently, no supplement has been approved as a first-line treatment for CIPN by major oncology groups. The information reviewed below is early research and should work with standard care, not replace it.
Why Oxaliplatin Damages Nerves
Oxaliplatin works against cancer by binding to DNA and blocking cell replication. However, the drug can also accumulate in the dorsal root ganglia-clusters of nerve cells near the spinal cord that process sensory signals such as touch, temperature, and pain. There, oxaliplatin generates reactive oxygen species, which are unstable molecules that damage cell membranes, mitochondria, and the myelin sheath-the protective coating around nerve fibers.
This oxidative damage is why antioxidant compounds such as curcumin and quercetin are studied in this setting. A 2025 systematic review and meta-analysis of randomized controlled trials found that antioxidant interventions were linked to reduced severe CIPN in colorectal cancer patients treated with oxaliplatin. This supports the scientific rationale for studying antioxidant nutrients as a complementary approach.
Curcumin: What the Evidence Shows
Curcumin is the primary bioactive polyphenol in turmeric. It has been studied for its antioxidant, anti-inflammatory, and neuroprotective properties. For CIPN, evidence comes from both preclinical studies and limited clinical trials.
Animal studies have found that curcumin reduced oxaliplatin accumulation in the sciatic nerve in rat models and was linked to reduced signs of nerve cell injury. A double-blind randomized controlled trial published in 2025 enrolled 141 pediatric patients with acute lymphoblastic leukemia receiving vincristine-another chemotherapy drug that causes peripheral neuropathy. The curcumin group received 3 mg/kg of oral curcumin capsules twice daily for three months. The trial found that curcumin was linked to lower rates of peripheral neuropathy compared to placebo.
This result has real limits for colorectal cancer survivors. The trial involved children, and vincristine works differently from oxaliplatin. No large-scale clinical trial of curcumin specifically in adult colorectal cancer patients with oxaliplatin-induced CIPN has been completed as of now. However, the shared mechanism-antioxidant protection of peripheral nerve tissue-overlaps with the pathway involved in oxaliplatin neuropathy. The 2025 systematic review on antioxidant therapies in CRC patients supports this research direction.
One practical issue with curcumin is bioavailability. A review of curcumin formulations for neuropathic pain noted that standard curcumin has low oral bioavailability, meaning a large portion is broken down before reaching the bloodstream. Enhanced formulations-such as the BCM-95 preparation, which combines curcumin with turmeric essential oils to improve absorption-have been developed to address this. When evaluating formulation options, enhanced-bioavailability curcumin products like BCM-95 are available. Dose and timing should be confirmed with your oncologist, as curcumin at high doses may interact with anticoagulants and some chemotherapy drugs.
Quercetin: Early-Stage Evidence for Nerve Support
Quercetin is a plant flavonoid found in apples, onions, capers, and leafy greens. It has been studied for antioxidant, anti-inflammatory, and pain-modulating properties relevant to nerve damage.
In rat models of peripheral neuropathy, quercetin administered at 30 to 60 mg/kg per day improved nerve conduction velocity and reduced nerve cell damage. The proposed mechanism involves activation of the AMPK/PGC-1alpha pathway, which supports mitochondrial function and reduces oxidative stress in nerve tissue. A separate preclinical study found that quercetin reduced cisplatin-induced neuropathy in rats by targeting oxidative stress and cell death pathways.
Human clinical data for quercetin specifically in CIPN are limited. A registered clinical trial (NCT02989129) is examining quercetin for treating and preventing chemotherapy-induced neuropathic pain in cancer patients, with quercetin tablets administered twice daily for 12 weeks. As of this article’s publication, completed results from large-scale human trials of quercetin for oxaliplatin-induced CIPN have not been widely published. No major oncology guideline includes quercetin as a recommended treatment for CIPN.
B Vitamins: B6 and B12 in Nerve Health
Vitamins B6 (pyridoxine) and B12 (cobalamin) are essential for maintaining the myelin sheath and supporting neurotransmitter synthesis. Both deficiency and excess of these vitamins can affect nerve health.
A 2025 prospective cohort study followed 242 patients with non-metastatic colorectal cancer receiving oxaliplatin-based chemotherapy. The study found that low plasma vitamin B6 levels were linked to the development of chronic CIPN. This does not confirm that B6 supplements will prevent or reverse CIPN, but it identifies low B6 status as a potentially modifiable factor worth monitoring during and after oxaliplatin treatment.
Regarding vitamin B12: a review of B12 in cancer patients noted that B12 deficiency can produce symptoms that overlap with CIPN-including numbness and tingling in the extremities-and that an existing B12 deficiency may worsen treatment-related neuropathy. Patients on long-term metformin or proton pump inhibitors are at higher risk for B12 depletion and may benefit from routine monitoring during and after chemotherapy.
An important safety note for B6: the NIH Office of Dietary Supplements documents a Tolerable Upper Intake Level of 100 mg per day for adults. Supplemental B6 above this level may itself cause peripheral neuropathy-the opposite of the intended effect. B6 supplementation during cancer care should only be considered with a confirmed deficiency and a dose agreed upon by your clinician. B12 is generally well tolerated at supplemental doses.
What the Evidence Does Not Yet Confirm
Several important limitations apply to this area of research:
- Most curcumin CIPN data come from animal studies or human trials using a different chemotherapy drug. No large-scale adult trial in oxaliplatin-induced CIPN has been completed.
- Quercetin human clinical trial results for CIPN have not been widely published. Animal dose data cannot be directly applied to human supplementation.
- The B6 cohort data shows an association between low B6 status and CIPN risk, not proof that B6 supplements prevent or treat CIPN.
- Bioavailability and formulation quality affect whether a compound reaches useful levels in the body.
- Interactions between these compounds and active or recent chemotherapy drugs are not fully mapped. Individual risk depends on your specific regimen.
Survivors managing the long-term effects of oxaliplatin may also benefit from addressing nutritional status more broadly. For related guidance on supporting the body during colorectal chemotherapy, see the article on protein strategies to prevent muscle loss during colorectal chemo.
Talking to Your Care Team
CIPN after colorectal cancer treatment is best managed as a partnership with your oncology team. Standard medical options include duloxetine (a prescription medication with evidence for CIPN-related pain) and physical or occupational therapy to support daily function. These remain the first-line tools in current clinical guidance. Curcumin, quercetin, and B vitamins are adjunct considerations-areas of ongoing research, not established treatments.
Survivors looking at gut health recovery alongside nerve damage management may also find the article on colorectal cancer survivorship and microbiome recovery useful for a complementary set of post-treatment considerations.
If you are evaluating nutraceutical options for recovery support, you can browse available nutraceuticals, which include curcumin and quercetin formulations alongside other evidence-studied compounds. A quality formulation and clinician review of dose and timing are important steps before starting any supplement during or after cancer treatment.
If you are taking prescription medications, are pregnant, or are breastfeeding, speak with a clinician before starting any supplement regimen.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
